Impact Biomedical IBO
NYSE IBO
$4.02 +0.22 (+5.78%)
As of: Oct 23, 2026 · 1:02 PM EDT

Impact Biomedical (IBO) Capital Expenditures (2023)

Updated

Impact Biomedical (IBO) posted Capital Expenditures of $18,000 for FY2023, down 93.5% from $276,000 in FY2022.

Analysis

Impact Biomedical (IBO) Capital Expenditures (2023) Analysis & Trends

  • Business Quant data shows IBO's Capital Expenditures at $276,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,129.65 Bn 1,098.23 Bn 19.71 Bn 2.93 Bn
2 Johnson & Johnson 635.30 Bn 555.16 Bn 17.30 Bn 1.36 Bn
3 AbbVie 504.45 Bn 477.56 Bn 12.70 Bn 322.00 Mn
4 Merck 358.32 Bn 312.70 Bn 12.21 Bn 893.00 Mn
5 Novartis Ag 290.03 Bn 254.02 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 265.08 Bn 238.77 Bn 12.86 Bn 1.86 Bn
7 Amgen 237.81 Bn 193.21 Bn 7.24 Bn 513.00 Mn
8 Gilead Sciences 194.88 Bn 169.07 Bn 6.22 Bn 140.00 Mn
9 Pfizer 171.37 Bn 118.01 Bn 10.94 Bn 533.00 Mn
10 Impact Biomedical 433.42 Mn 433.37 Mn 2,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 1,000.00
Jun 30, 2023 12,000.00
Mar 31, 2023 5,000.00
API Access

Impact Biomedical Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IBO&period=max&api_key=YOUR_API_KEY